Anthem Biosciences Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 29,708,332 (50%) | — | ₹169,337 Cr |
| NII (HNI) | — | 8,912,500 (15%) | — | ₹50,801 Cr |
| Retail | — | 20,795,834 (35%) | — | ₹118,536 Cr |
| Employee | — | 158,653 (0%) | — | ₹90 Cr |
| Σ Total | — | 59,575,319 (100%) | — | ₹3,395,793 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 26 | ₹14,820 |
| Retail (Max) | 13 | 338 | ₹192,660 |
| S-HNI (Min) | 14 | 364 | ₹207,480 |
| B-HNI (Min) | 67 | 1,742 | ₹992,940 |
Financial Statements Amount in Crore
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 1,930 | 1,483 | 1,134 |
| EBITDA | 684 | 520 | 446 |
| Profit After Tax | 451 | 367 | 385 |
| Net Worth | 2,410 | 1,925 | 1,741 |
| Total Assets | 2,808 | 2,398 | 2,014 |
| Reserves & Surplus | 2,298 | 1,815 | 1,629 |
| Total Borrowing | 109 | 233 | 125 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 To achieve the benefits of listing the Equity Shares on the Stock Exchanges –
Company Overview
Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) with fully integrated operations encompassing drug discovery, development, and manufacturing processes.
The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale.
The company manufactures specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
For the six months concluding on September 30, 2024, the company engaged in the manufacture of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been supported since their discovery.
As of September 30 2024, the company had 196 projects: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).
As of September 30 and March 31, 2024, the company had over 425 and 550 customers in our CRDMO and specialty ingredients businesses, spanning more than 44 countries, including the U.S., Europe, and Japan.
As of March 31, 2024, the company served over 150 customers, from small biotech to large pharmaceutical companies.
As of September 30, 2024, the company holds one patent in India, seven overseas, and has 24 pending global patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.
As of September 30 2024, the company's team consists of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, experts in various in-vivo non-clinical research and chemical engineers.
Competitive Strength
- One-stop service across the drug life cycle (discovery, development, manufacturing) for small molecules and biologics; we are India's fastest growing CRDMO.
- Innovation-focused approach has enabled us to offer a spectrum of technologically advanced solutions across modalities and manufacturing practices.
- Specialized business model for small pharmaceutical and biotech companies, from discovery to manufacturing.
- Long-standing relationships with a large, diversified and loyal customer base.
- Professional and experienced leadership team supported by a qualified scientific talent pool.